Chemotherapy and radiotherapy: Cryptic anticancer vaccines

Abstract An attractive, yet hitherto unproven concept predicts that the promotion of tumor regression should elicit the host's immune response against residual tumor cells to achieve an optimal therapeutic effect. In a way, chemo- or radiotherapy must trigger “danger signals” emitted from immun...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in immunology 2010-06, Vol.22 (3), p.113-124
Main Authors: Ma, Yuting, Kepp, Oliver, Ghiringhelli, François, Apetoh, Lionel, Aymeric, Laetitia, Locher, Clara, Tesniere, Antoine, Martins, Isabelle, Ly, André, Haynes, Nicole M, Smyth, Mark J, Kroemer, Guido, Zitvogel, Laurence
Format: Article
Language:English
Subjects:
Allergy and Immunology
Cancer
Cancer Vaccines - immunology
Cell death
Chemotherapy
Drug Therapy
Humans
Immune System
Immunotherapy - methods
Inflammasome
Interferon-gamma - metabolism
Interferon-γ
Interleukin-1beta - metabolism
Interleukin-1β
Neoplasms - immunology
Neoplasms - therapy
Radiotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract An attractive, yet hitherto unproven concept predicts that the promotion of tumor regression should elicit the host's immune response against residual tumor cells to achieve an optimal therapeutic effect. In a way, chemo- or radiotherapy must trigger “danger signals” emitted from immunogenic cell death and hence elicit “danger associated molecular patterns” to stimulate powerful anticancer immune responses. Here, based on the recent experimental and clinical evidence, we will discuss the molecular identity of the multiple checkpoints that dictate the success of “immunogenic chemotherapy” at the levels of the drug, of the tumor cell and of the host immune system.
ISSN:1044-5323
1096-3618
DOI:10.1016/j.smim.2010.03.001